In our future studies, we will conduct ChIP-seq analysis of TGFβ/SMAD4 binding sites using a panel of ovarian cancer cell lines representing different histological subtypes and ovarian cancer initiating cells. This evidence concerns the gene SMAD4 and ovarian carcinoma.